Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
“Histologic transformation to small cell lung cancer (SCLC) is a mechanism of treatment resistance in patients with advanced oncogene-driven lung adenocarcinoma (LUAD) that currently requires histologic review for diagnosis. Herein, we sought to develop an epigenomic cell-free DNA (cfDNA)-based approach to noninvasively detect small cell transformation in patients with EGFR mutant (EGFRm) LUAD.”
Adjuvant Chemotherapy May Have Survival Benefit in Stage III Locally Advanced NSCLC
“Favorable recurrence-free survival and overall survival outcomes were not observed in the overall patient cohort receiving adjuvant chemotherapy for advanced NSCLC.”
Incidence of and predictive factors for lung cancer in patients with rheumatoid arthritis: A retrospective long-term follow-up study
“Close monitoring of lung cancer is needed for RA patients with smoking history and pulmonary complications, especially CPFE.”
Triplet Therapy Shows Promise in Advanced Lung Cancer
“A combination of an antibody-drug conjugate, immune checkpoint inhibitor and chemotherapy is showing promise for patients with metastatic non-small cell lung cancer. Results from the phase 2 EVOKE-02 study will be presented at the 2024 World Conference on Lung Cancer.”
Lung Cancer Cases Rising in Young Women of Asian and Latina Descent: What You Need to Know
“In the past 25 years, cases of lung cancer have been rising among people without previous tobacco use. These cancer cases are approximately 2.5 times more likely to be found in women than in men. These women tend to be younger, and cases are rising more rapidly in people of Asian or Hispanic/Latina descent.”
TGF-Beta and RAS Signaling Are Both Required for Lung Cancer Metastasis, Study Finds
“When it comes to cancer metastasis, it takes two to tango. That was one of the key findings of a new study led by researchers at Memorial Sloan Kettering Cancer Center (MSK): The TGF-beta and RAS signaling pathways work together to spur the spread of cancer in lung adenocarcinoma, a leading cause of cancer deaths around the world. Take away one of those two signals, and lung cancer will not be able to spread (metastasize) to new parts of the body, their findings in animal models suggest.”
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
“Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients. 12 mg/kg selected as optimal dose for extension part of IDeate-Lung01 phase 2 trial and recently initiated IDeate-Lung02 phase 3 study.”
Survey reveals progress and persistent barriers in lung cancer biomarker testing
“Despite significant improvements in the perception of biomarker testing compared to a 2018 survey, substantial barriers to implementation persist globally, according to results of the 2024 IASLC Global Survey on Biomarker Testing released today at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2024.”
Summit lung cancer drug shows ‘striking’ benefit over Keytruda
“An experimental medicine from a small biotechnology company cut the risk of lung cancer progression in half when tested against the world’s most dominant immunotherapy in a clinical trial, according to study data presented Sunday at a major medical meeting. The results come from a Phase 3 trial pitting a drug from biotech Summit Therapeutics against Merck & Co.’s Keytruda in people recently diagnosed with advanced non-small cell lung cancer. Data show Summit’s drug held tumors at bay for a median of just over 11 months, compared to almost six months for those given Keytruda. The 5.3-month difference in progression-free survival equated to a statistically significant 49% reduction in the risk of cancer progression or death.”
Deep Learning Models Expedite Biomarker Discovery, Detection in Lung Cancer
“In the first,1 investigators from China found a high degree of accuracy for detecting biomarkers using whole slide images (WSIs) obtained from lymph node biopsies. In the second,2 researchers from Australia analyzed the tumor and its microenvironment (TME) across patients who did or did not respond to checkpoint inhibitor therapy, which detected distinct metabolic patterns of response for immunotherapy.”
AstraZeneca says lung cancer drug trial shows no significant improvement in overall survival
“LONDON, Sept 9 (Reuters) – Detailed results from one of AstraZeneca’s (AZN.L), opens new tab key lung cancer trials released on Monday showed that its experimental precision drug did not significantly improve overall survival results for patients in the trial. The overall survival, or OS rates, in the TROPION-Lung01 trial “did not reach statistical significance”, the company said in a presentation at the World Conference on Lung Cancer in San Diego.”
